|
Unit:
|
Investment Service Center of Xianyou County
|
|
|
Project Area:
|
putian-xianyou Youyang Town
|
|
|
Industry:
|
Biological and New Pharmaceutical Industry
|
|
|
Type of Project:
|
New Project
|
|
|
Cooperation Mode:
|
Individual Proprietorship,Joint Venture,Collaborate
|
|
|
Nature of Project:
|
||
|
Working Progress in Prior Period:
|
The project plans to focus on the full three-industry integration chain of traditional Chinese medicine (TCM) in Xianyou County, with three core initiatives as follows: First, construct standardized Chinese medicinal herb planting bases and carry out larg
|
|
|
Total Investment:
|
3000 million yuan
|
|
|
Expected to Attract Investment:
|
3000 million yuan
|
|
|
Content and Scale:
|
The project plans to focus on the full three-industry integration chain of traditional Chinese medicine (TCM) in Xianyou County, with three core initiatives as follows: First, construct standardized Chinese medicinal herb planting bases and carry out large-scale cultivation of authentic regional medicinal herb varieties. Second, build modern processing plants for Chinese medicinal herbs to conduct primary and intensive processing of cultivated medicinal materials, as well as the R&D and production of various medicinal teas and medicinal diets. Third, integrate medicinal herb planting bases with TCM culture to develop a wellness complex integrating agricultural sightseeing, TCM culture popular science, study tours, health-preserving tourism, rehabilitation and recuperation services.
|
|
In 2025, Fujian Province had 341 above-designated-size pharmaceutical enterprises, achieving an operating revenue of RMB 50.28 billion. The province's pharmaceutical industry has cultivated a relatively comprehensive industrial system covering categories such as chemical APIs (active pharmaceutical ingredients), chemical drug preparations, biopharmaceuticals, traditional Chinese medicine (TCM) prepared prescriptions, TCM decoction pieces, and medical devices. During the "14th Five-Year Plan" period, 4 Category-1 innovative drugs and 4 Category-2 innovative drugs were approved, accelerating industrial innovation. Maxim Biotech and Double Medical were promoted as leaders in the industrial chain. 6 projects from 3 enterprises, including Double Medical, were shortlisted for the Ministry of Industry and Information Technology's List of “Open Bidding for Selecting the Best Candidates for Innovation Tasks in Biomedical Materials.” 11 provincial-level industrial leading enterprises in biomedicine, such as Zhangzhou Pien Tze Huang Pharmaceuticals, and 17 enterprises under cultivation for leading status were fostered. 3 enterprises, including AmoyDx, were recognized as national single-item champions (in specific products); 25 enterprises, including Fukang Pharmaceuticals, were recognized as provincial single-item champions (in specific products). 19 pharmaceutical enterprises, including Southern Pharmaceuticals and Fukang Pharmaceuticals, were recognized as National "Little Giants" Enterprises Using Specialized and Advanced Technologies to Create Innovative and Unique Products. 15 enterprises, including Double Medical, Cosunter Pharmaceutical, and Haixi Pharmaceuticals, are listed companies.